Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

LANTHEUS HOLDINGS, INC.

(LNTH)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

GE, Lantheus Say Heart Disease Tracer Trial Met Key Endpoints

09/13/2022 | 07:01am EST

By Dean Seal


General Electric Co.'s healthcare business and Lantheus Holdings Inc. said Tuesday that the Phase 3 clinical trial for their investigational radiotracer met co-primary endpoints in the detection of coronary artery disease.

The companies said the trial for the radiotracer, dubbed [18F]flurpiridaz, met the co-primary endpoints of exceeding a 60% threshold for both sensitivity and specificity for detecting heart disease.

The trial also met its first key secondary endpoint by demonstrating that [18F]flurpiridaz Positron Emission Tomography has higher diagnostic efficacy for patients with suspected coronary artery disease when compared with the predominant procedure used in nuclear cardiology today.

GE Healthcare has led the funding and development of the investigational agent and will have global commercialization rights to the imaging agent if it is approved. Lantheus has collaborated on the development and will work with GE on a potential commercialization through a joint steering committee, with entitlement to royalties based on commercial sales.


Write to Dean Seal at dean.seal@wsj.com


(END) Dow Jones Newswires

09-13-22 0901ET

Stocks mentioned in the article
ChangeLast1st jan.
GENERAL ELECTRIC COMPANY -2.61% 81.45 Delayed Quote.-11.47%
LANTHEUS HOLDINGS, INC. -0.37% 53.31 Delayed Quote.85.22%
All news about LANTHEUS HOLDINGS, INC.
12/08Lantheus Holdings, Inc. : Entry into a Material Definitive Agreement, Creation of a Direct..
AQ
12/06Lantheus Holdings Prices $500 Million Convertible Senior Notes Offering
MT
12/06Lantheus Holdings, Inc. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
12/06Lantheus Holdings, Inc. Announces Pricing of Offering of $500 Million Convertible Senio..
GL
12/05Sector Update: Healthcare Stocks Slide Monday but Outperform Most Sectors
MT
12/05Sector Update: Health Care Stocks Pulled Lower by Sinking Biotechs
MT
12/05Lantheus Holdings Shares Drop 10% After Planned Senior Notes Offering
DJ
12/05Sector Update: Health Care Stocks Flat to Lower Pre-Bell Monday
MT
12/05Lantheus Holdings Plans to Offer $500 Million of Convertible Notes
MT
12/05Lantheus Holdings, Inc. : Entry into a Material Definitive Agreement, Termination of a Mat..
AQ
More news
Analyst Recommendations on LANTHEUS HOLDINGS, INC.
More recommendations
Financials (USD)
Sales 2022 917 M - -
Net income 2022 200 M - -
Net Debt 2022 - - -
P/E ratio 2022 18,9x
Yield 2022 -
Capitalization 3 669 M 3 669 M -
Capi. / Sales 2022 4,00x
Capi. / Sales 2023 3,55x
Nbr of Employees 612
Free-Float 97,6%
Chart LANTHEUS HOLDINGS, INC.
Duration : Period :
Lantheus Holdings, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LANTHEUS HOLDINGS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 53,31 $
Average target price 101,67 $
Spread / Average Target 90,7%
EPS Revisions
Managers and Directors
Mary Anne Heino Chief Commercial Officer
Robert J. Marshall Chief Financial Officer & Treasurer
Brian A. Markison Director
Simon Robinson Senior VP-Research & Pharmaceutical Development
Bela S. Denes Vice President-Medical Affairs
Sector and Competitors